Reata says waiting period related to merger under Hart-Scott-Rodino act expired

In a regulatory filing, Reata Pharmaceuticals (RETA) noted that, as previously disclosed on July 28, the company, Biogen (BIIB), and River Acquisition, a Delaware corporation and a wholly-owned subsidiary of Biogen, entered into an agreement and plan of merger, pursuant to which, and upon the terms and subject to the conditions set forth therein, merger sub will be merged with and into Reata, with Reata surviving the merger as a wholly-owned subsidiary of Biogen. “The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the merger expired at 11:59 p.m. Eastern Time on September 11, 2023. The consummation of the merger remains subject to other customary closing conditions specified in the merger agreement, including, among others, receipt of the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Class A common stock, par value $0.001 per share, and the outstanding shares of Class B common stock, par value $0.001 per share, of Reata to adopt the merger agreement and approve the transactions contemplated thereby. As previously disclosed, a special meeting of the stockholders of Reata in connection with the proposed merger has been scheduled to be held virtually via live webcast at 8:00 a.m. Central Time on September 21,” the filing stated.